The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
About this item
Full title
Author / Creator
Wei, Qing , Li, Peijing , Yang, Teng , Zhu, Jiayu , Sun, Lu , Zhang, Ziwen , Wang, Lu , Tian, Xuefei , Chen, Jiahui , Hu, Can , Xue, Junli , Ma, Letao , Shimura, Takaya , Fang, Jianmin , Ying, Jieer , Guo, Peng and Cheng, Xiangdong
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both prec...
Alternative Titles
Full title
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_66d0042687784ac5a8494718d389400a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_66d0042687784ac5a8494718d389400a
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-023-01509-2
